Intense immune suppression for systemic lupus - The role of hematopoietic stem cells

Journal of Clinical Immunology

Volumn 20, Issue 1, 2000, Pages 31-37

  Burt, Richard K ^a   Marmont, Alberto ^b   Schroeder, James ^a   Rosa, Robert ^a   Traynor, Ann E ^a  

^a NORTHWESTERN UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Hematopoietic stem cell transplantation; Immune suppression; Systemic lupus

Indexed keywords

CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; THYMOCYTE ANTIBODY;

ARTICLE; AUTOTRANSPLANTATION; DRUG MEGADOSE; FEMALE; GRAFT INFECTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; MALE; NONHUMAN; PRIORITY JOURNAL; REMISSION; RISK BENEFIT ANALYSIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; TRANSPLANTATION CONDITIONING;

EID: 0034120525     PISSN: 02719142     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006638510160     Document Type: Article

References (45)

1. 1. Alarcon-Segovia D, Alarcon-Riquelme ME: Ethiopathogenesis of systemic lupus erythematosus: A tale of three troikas. In Systemic Lupus Erythematosus, Lahita RG (ed). San-Diego-Toronto, Academic Press, 1999, pp 55-65
2. 2. Rose NR and Bona C: Defining criteria for autoimmune diseases (Witebsky's postulates revisited), Immunology Today 14:426-429, 1993
3. 3. Dang H, Harbeck RJ: The in vivo and in vitro glomerular deposition of isolated anti-double-stranded DNA antibodies in NZB/W mice. Clin Immunol Immunopathol 31:265-278, 1984
4. 4. Ehrenstein MR, Katz DR, Griffiths M, Winkler TH, Kalden JR, Tsenberg DA: Human monoclonal IgG anti-DNA antibodies deposit in kidneys and induce proteinuria in SCID mice (abst). Lupus 4(Suppl 2):69, 1995
5. 5. Marmont AM: The transfusion of active LE plasma into nonlupus recipientys, with a note on the LE-like cell. Annals New York Academy of Sciences, 124:838-851, 1965
6. 6. Ward MM, Pisetsky DS, Christenson VD: Antidouble stranded DNA antibody assays in systemic lupus erythematosus: correlations of longitudinal antibody measurements. J Rheumatol 16: 609-613, 1989
7. 7. Dubois EL, Commons RR, Star P, Stein CS Jr, Morrison R: Corticotropin and cortisone treatment for systemic lupus erythematosus. JAMA 149:995-1002, 1952
8. 8. Ben-Asher S: Recurrent acute lupus erythematosus disseminatus: Report of case which has survived 23 years after onset of systemic manifestations. Ann Intern Med 34:243-248, 1951
9. 9. Wallace DJ, Podell T, Weiner J, Klinenberg JR, Forouzesh S, Duboius EL: Systemic lupus erythematosus-survival patterns. Experience with 609 patients. JAMA 245:934-938, 1981
10. 10. Bielschowsky M, Helyer BJ, Howie JB: Spontaneous haemolytic anaemia in mice of the NZB/BI strain. Proc Univ Otago Med Sch (NZ) 37:9-11, 1959
11. 11. Yoshida S, Castles JJ, Gershwin ME: The pathogenesis of autoimmunity in New Zealand mice. Semin Arthritis Rheum 19:224-242, 1990
12. 12. Kono DH, Burlingame RW, Owens DG, Kuramochi A, Balderas RS, Balomenos D, Theofilopoulos AN: Lupus susceptibility loci in New Zealand mice. Proc Natl Acad Sci USA 91:10,168-10,172, 1994
13. 13. Eastcott JW, Scxhwartz RS, Datta SK: Genetic analysis of the inheitance of B cell hyperactivity in relation to the development of autoantibodies and glomerulonephritis in NZB × SWR crosses. J Immunol 131:2232-2239, 1983
14. 14. Murphy ED, Roths JB: A single gene for massive lymphoproliferation with immune complex disease in a new mouse strain MRL. In Proceedings of the 16th International Congress in Hematology. Amsterdam, Excerpta Medica, pp 69-80, 1976
15. 15. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S: Lymphoproliferative disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356:314-317, 1992
16. 16. Makin M, Fumiwara M, Watanabe H: Studies on the mechanisms of the development of lupus nephritis in BXSB mice. I. Analysis of immunological abnormalities at the onset period. J Clin Lab Immunol 22:127-131, 1987
17. 17. Murphy ED, Roths JB: A Y chromosome associated factor in strain BXSB producing accelerated autoimmunity and lymphoproliferation. Arthritis Rheum 22:1188-1194, 1979
18. 18. Hashimoto Y, Kawamura M, Ichikawa K, Suzuki T, Sumida T, Toshida S, Matsuura E, Ikehara S, Koike T: Anticardiolipin antibodies in NZW × BXSB F1 mice. A model of antiphospholipid syndrome. J Immunol 149:1063-1068, 1992
19. 19. Ikehara S, Nakamura T, Sekita K, Muso E, Hasunizu R, Ohtsuki H, Hamashima Y, Good R: Treatment of systemic and organ-specific autoimmune disease in mice by allogeneic bone marrow transplantation. Prog Clin Biol Res 229:131-146, 1987
20. 20. Himeno K, Good RA: Marrow transplantation from tolerant donors to treat and prevent autoimmune diseases in BXSB mice. Proc Natl Acad Sci USA 85:2235-2239, 1988
21. 21. Karussis DM, Vourka-Karussis U, Lehmann D, Abramsky O, Ben-Nun A, Slavin S: Immunomodulation of autoimmunity in MRL/Ipr mice with syngeneic bone marrow transplantation (SBMT). Clin Exp Immunol 100:111-117, 1995
22. 22. Ishida T, Inaba M, Hisha H, Sugiura K, Adachi Y, Nagata N, Ogawa R, Good RA, Ikahara S: Requirement of donor-derived stromal cells in the bone marrow for successful allogeneic bone marrow transplantation. Complete prevention of recurrence of autoimmune diseases in MRL/MP-Ipr/Ipr mice by transplantation of bone marrow plus bones (stromal cells) from the same donor. J Immunol 152:3119-3127, 1994
23. 23. Deapen D, Escalante A, Weinrib L, Horowitz D, Bachman B, Roy-Burman P, Walker A, Mack TM: A revised estimate of twin concordance in systemic lupus erythematosus. Arthritis Rheum 35:311-318, 1992
24. 24. Bock SR, Winfield JB, Lockshin MD, D'Angelo WA, Christian CL: Studies of twins with systemic lupus erythematosus. A review of the literature and presentation of 12 additional sets. Am J Med 59:533-552, 1975
25. 25. Rajagopalan S, Zordan T, Tsokos GC, Datta SK: Pathogenic anti-DNA autoantibody-inducing T helper lines from patients with active lupus nephritis: Isolation of CD8-T helper cell lines that express the gamma delta T-cell antigen receptor. Proc Natl Acad Sci USA 87:7020, 1990
26. 26. Vassilopoulos D, Kovacs B, Tsokos GC: TCR/CD3 complex-mediated signal transduction pathway in T cells and cell lines from patients with systemic lupus erythematosus. J Immunol 155:2269, 1995
27. 27. Liossis SN, Ding DZ, Dennis GJ, Tsokos GC: Altered pattern of TCR/CD3-mediated protein-tyrosyl phosphorylation in T cells from patients with systemic lupus erythematosus. Deficient expression of the T cell receptor zeta chain. J Clin Invest 101:1448, 1998
28. 28. Rengaraju M, Gray JD, Horwitz DA, Kubin M, Trinchierir G: Increased spontaneous IL-10 production and decreased mitogen-induced INFγ and TNFα production in untreated patients with SLE: Role of CD8+ T cells. Lupus 4(suppl 2):82, 1995
29. 29. Berstein RM, Hobbs RN, Lee DJ, Ward DJ, Hughes GRV: Patterns of antihistone antibody specificity in systemic rheumtic disease. I. Systemic lupus erythematosus, mixed connective tissue disease, primary sicca syndrome, and rheumatoid arthritis with vasculitis. Arthritis Rheum 28:285-293, 1985
30. 30. Marmont AM: New horizons in the treatment of autoimmune diseases: Immunoablation and stem cell Transplantation. Ann Rev Med 51:115-134, 2000
31. 31. Symmons DPM, Coopock JS, Bacon PA, Bresnihan B, Isenberg DA, Maddison P, Mchugh N, Snaith ML, Zoma AS: Development and assessment of a computerized index of clinical disease activity in systemic lupus erythematosus. QJ Med 68:927-937, 1988
32. 32. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH: Derivation of the SLEDAI. A disease activity index for lupus patients. The committee on prognosis studies in SLE. Arthritis Rheum 35:630-640, 1992
33. 33. Liang MH, Socher SA, Roberts WN, Esdaile JM: Measurement of systemic lupus erythematosus activity in clinical research. Arthritis Rheum 31:817-825, 1988
34. 34. Petri M, Bochemstedt L, Colman J, Whiting-O'Keefe Q, Fitz G, Sebastin A, Hellman D: Serial assessment of glomerular filtration rate in lupus nephropathy. Kidney Int 34:832-839, 1988
35. 35. Gladman DD, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowtz M, Bacon P, Bombardi S, Hanly J, Hay E, Isenberg J, Jones J, Kalunian K, Maddison P, Nived OT, Petri M, Richter M, Sanchez-Guerrero J, Snaith M, Sturfelt G, Symmons D, Zoma A: The development and international validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index for systemic lupus erythematosus. Arthritis Rheum 39:363-369, 1996
36. 36. Ginzler EM, Diamond HS, Weiner M, Schlesinger M, Fries JF, Wasner C, Medsger TA Jr, Zieger G, Klippel JH, Hadler NM, Albert DA, Hess EV, Spencer-Green G, Grayzel A, Worth D, Hahn BH, Barnett EV: A multicenter study of outcome of systemic lupus erythematosus. I. Entry variables as predictors of progress. Arthritis Rheum 25:601-611, 1982
37. 37. Abu-Shakra M, Urowitz MB, Gladman DD, Gough J: Mortality studies in systemic lupus erythematosus. Results from a single center. II. Predictor variables for mortality. J Rheumatol 22:1265-1270, 1995
38. 38. Harisdangkul V, Nilganuwonge S, Rockhold L: Cause of death in systemic lupus erythematosus: A pattern based on age at onset. South Med J 80:1249-1253, 1987
39. 39. Marmont AM, van Lint MT, Gualandi F, Bacigalupo A: Autologous marrow stem cell transplantation for severe systemic lupus erythematosus of long duration. Lupus 6:545-548, 1997
40. 40. Fouillard L, Gorin NC, Laporte JP, Leon A, Brantus JF, Miossec P: Control of severe systemic lupus erythematosus after high dose immunosuppressive therapy and transplantation of CD34+ purified autologous stem cells from peripheral blood. Lupus 8:320-323, 1999
41. 41. Burt RK, Traynor AE, Ramsey-Goldman R: Hematopoietic stem-cell transplantation for systemic lupus erythematosus (letter). New England Journal of Medicine 337:1777-1778, 1997
42. 42. Burt RK, Traynor AE, Pope R, Schroeder J, Cohen B, Karlin KH, Lobeck L, Goolsby C, Rowlings P, Davis FA, Stefoski D, Terry C, Keever-Taylor C, Rosen S, Vesole D, Fishman M, Brush M, Mujias S, Villa M, Burns WH: Treatment of autoimmune disease by intense immunosuppressive conditioning and autologous hematopoietic stem cell transplantation. Blood 92:3505-3514, 1998
43. +) cell transplantation for systemic lupus erythematosus complicated by Evans syndrome. Lupus 7:492-494, 1998
44. 44. Brodsky RA, Petri M, Smith BD, Steifter J, Spivak JL, Styler M, Dang CV, Bridsky I, Jones R: Immunablative high dose cyclophosphamide without stem cell rescue for refractory severe autoimmune disease. Ann Intern Med 129:1031-1035, 1998
45. 45. Burt RK, Traynor AE: Hematopoietic stem cell therapy of autoimmune disease. Current Opinion in Hematology 5:472-477, 1998